DICE Therapeutics’ $204 Million Initial Public Offering

Fenwick & West advised DICE Therapeutics on the deal.DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel…

This content is for Standard 1 Year members only.
Login Join Now

Boeing’s Securities Fraud

Bite’s $9 Million Series A Funding Round

Nordstrom’s Take-Private Proposal

ICC Inversiones’ Acquisition of 20,1% Stake in Grupo Patio SpA

Transocean’s $1.8 Billion Senior Notes Offering and Cash Tender Offers

GDM’s Acquisition of KWS’s Corn and Sorghum Business in South America

Gridbeyond Limited’s Series C Investment Round

Greensleeves’ Acquisition of Broadacres

Zambia’s Restructuring of Sovereign Bond

KOKO Networks Limited’s Financing Round

India Vehicle Finance’s Notes Offering

Al-Arafa’s Demerger into Concrete Fashion Group and GTEX

SC Ventures’ $100 Million Joint Venture With SBI Holdings

GreenCorp’s Acquisition of Emad Bakeries

Guesty’s Financing Round

Viva Energy Group’s Acquisition of OTR Group

Lanyon RE Services Limited’s Merger of Five Managed Investment Schemes

Mapletree Treasury Services and Mapletree Investments’ Revolving Credit Facilities

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Hefesto Asesores continues to consolidate its position in the International Private Equity and Venture Capital market, with the formation of Hefesto Global

Paul Hastings Adds Premier Private Equity Buyout Team

The Distinctive Character Of The ‘Vespa’ Is No Longer In Question

Cultural Heritage Sites With Restrictions On Intended Use: The Council of State Acknowledges That This Power Lies In the Hands Of The Ministry Of Culture

The Italian Revenue Agency Qualifies Directors’ Reversible Remuneration For The Purposes Of Double Taxation Agrements.

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Paul Hastings Adds Premier Private Equity Buyout Team

BCLP Appoints Trevor Varnes as Chief Financial Officer

DICE Therapeutics’ $204 Million Initial Public Offering

Author: Martina Bellini